The Role of RNA Interference Therapeutics in Hypercholesterolemia and Implications for Practice

An estimated 80% of patients with dyslipidemia do not reach their targeted low-density lipoprotein-cholesterol goals. Despite the use of traditional lipid-lowering therapies, challenges exist in getting patients to goal. Long-acting RNA interference (RNAi) therapeutics represent the next generation of medication that can provide up to 50% reduction of low-density lipoprotein-cholesterol, with few adverse effects for patients who need additional therapy or are intolerant or nonadherent to statin therapy.
Source: The Journal for Nurse Practitioners - Category: Nursing Authors: Tags: Featured Article Source Type: research